These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 38644564)

  • 1. Relative Effectiveness of the MF59®-Adjuvanted Influenza Vaccine Versus High-Dose and Non-Adjuvanted Influenza Vaccines in Preventing Cardiorespiratory Hospitalizations During the 2019-2020 US Influenza Season.
    Imran M; Puig-Barbera J; Ortiz JR; Lopez-Gonzalez L; Dean A; Bonafede M; Haag MDM
    Influenza Other Respir Viruses; 2024 Apr; 18(4):e13288. PubMed ID: 38644564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A clinical and economic assessment of adjuvanted trivalent versus standard egg-derived quadrivalent influenza vaccines among older adults in the United States during the 2018-19 and 2019-20 influenza seasons.
    Levin MJ; Divino V; Postma MJ; Pelton SI; Zhou Z; DeKoven M; Mould-Quevedo J
    Expert Rev Vaccines; 2024; 23(1):124-136. PubMed ID: 38073493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative Effectiveness of MF59 Adjuvanted Trivalent Influenza Vaccine vs Nonadjuvanted Vaccines During the 2019-2020 Influenza Season.
    Imran M; Puig-Barbera J; Ortiz JR; Fischer L; O'Brien D; Bonafede M; Mansi JA; Boikos C
    Open Forum Infect Dis; 2022 May; 9(5):ofac167. PubMed ID: 35493131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative Effectiveness of Adjuvanted Trivalent Inactivated Influenza Vaccine Versus Egg-derived Quadrivalent Inactivated Influenza Vaccines and High-dose Trivalent Influenza Vaccine in Preventing Influenza-related Medical Encounters in US Adults ≥ 65 Years During the 2017-2018 and 2018-2019 Influenza Seasons.
    Boikos C; Fischer L; O'Brien D; Vasey J; Sylvester GC; Mansi JA
    Clin Infect Dis; 2021 Sep; 73(5):816-823. PubMed ID: 33605977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative vaccine effectiveness of MF59-adjuvanted vs high-dose trivalent inactivated influenza vaccines for prevention of test-confirmed influenza hospitalizations during the 2017-2020 influenza seasons.
    McGovern I; Chastek B; Bancroft T; Webb N; Imran M; Pelton SI; Haag MDM
    Int J Infect Dis; 2024 Sep; 146():107160. PubMed ID: 38969330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of high dose versus adjuvanted influenza vaccine: A retrospective cohort study.
    van Aalst R; Gravenstein S; Mor V; Mahmud SM; Wilschut J; Postma M; Chit A
    Vaccine; 2020 Jan; 38(2):372-379. PubMed ID: 31606249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine over Three Consecutive Influenza Seasons in the United States.
    Boikos C; McGovern I; Ortiz JR; Puig-Barberà J; Versage E; Haag M
    Vaccines (Basel); 2022 Sep; 10(9):. PubMed ID: 36146534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing the Clinical and Economic Outcomes Associated with Adjuvanted versus High-Dose Trivalent Influenza Vaccine among Adults Aged ≥ 65 Years in the US during the 2019-20 Influenza Season-A Retrospective Cohort Analysis.
    Levin MJ; Divino V; Shah D; DeKoven M; Mould-Quevedo J; Pelton SI; Postma MJ
    Vaccines (Basel); 2021 Oct; 9(10):. PubMed ID: 34696254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial.
    Vesikari T; Kirstein J; Devota Go G; Leav B; Ruzycky ME; Isakov L; de Bruijn M; Oberye J; Heijnen E
    Lancet Respir Med; 2018 May; 6(5):345-356. PubMed ID: 29631857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative Effectiveness of the Cell-Based Quadrivalent Influenza Vaccine in Preventing Cardiorespiratory Hospitalizations in Adults Aged 18-64 Years During the 2019-2020 US Influenza Season.
    Imran M; Puig-Barbera J; Ortiz JR; Lopez-Gonzalez L; Dean A; Bonafede M; Haag M
    Open Forum Infect Dis; 2023 Jul; 10(7):ofad304. PubMed ID: 37496602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A retrospective cohort study assessing relative effectiveness of adjuvanted versus high-dose trivalent influenza vaccines among older adults in the United States during the 2018-19 influenza season.
    Pelton SI; Divino V; Postma MJ; Shah D; Mould-Quevedo J; DeKoven M; Krishnarajah G
    Vaccine; 2021 Apr; 39(17):2396-2407. PubMed ID: 33810903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of the Adjuvanted Influenza Vaccine in Older Adults at High Risk of Influenza Complications.
    Boikos C; Imran M; Nguyen VH; Ducruet T; Sylvester GC; Mansi JA
    Vaccines (Basel); 2021 Aug; 9(8):. PubMed ID: 34451987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: A systematic review and meta-analysis.
    Domnich A; Arata L; Amicizia D; Puig-Barberà J; Gasparini R; Panatto D
    Vaccine; 2017 Jan; 35(4):513-520. PubMed ID: 28024956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, Reactogenicity, and Health-Related Quality of Life After Trivalent Adjuvanted vs Trivalent High-Dose Inactivated Influenza Vaccines in Older Adults: A Randomized Clinical Trial.
    Schmader KE; Liu CK; Harrington T; Rountree W; Auerbach H; Walter EB; Barnett ED; Schlaudecker EP; Todd CA; Poniewierski M; Staat MA; Wodi P; Broder KR
    JAMA Netw Open; 2021 Jan; 4(1):e2031266. PubMed ID: 33443580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-licensure surveillance of trivalent adjuvanted influenza vaccine (aIIV3; Fluad), Vaccine Adverse Event Reporting System (VAERS), United States, July 2016-June 2018.
    Haber P; Moro PL; Ng C; Dores GM; Lewis P; Cano M
    Vaccine; 2019 Mar; 37(11):1516-1520. PubMed ID: 30739795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Effectiveness of Influenza Vaccines Among US Medicare Beneficiaries Ages 65 Years and Older During the 2019-2020 Season.
    Izurieta HS; Lu M; Kelman J; Lu Y; Lindaas A; Loc J; Pratt D; Wei Y; Chillarige Y; Wernecke M; MaCurdy TE; Forshee R
    Clin Infect Dis; 2021 Dec; 73(11):e4251-e4259. PubMed ID: 33211809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of aIIV3, MF59-adjuvanted seasonal trivalent influenza vaccine, in older adults ≥65 years of age: Meta-analysis of cumulative clinical experience.
    Nicolay U; Heijnen E; Nacci P; Patriarca PA; Leav B
    Int J Infect Dis; 2019 Aug; 85S():S1-S9. PubMed ID: 30926542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relative Effectiveness of Cell-based Versus Egg-based Quadrivalent Influenza Vaccines in Children and Adolescents in the United States During the 2019-2020 Influenza Season.
    Imran M; Ortiz JR; McLean HQ; Fisher L; O'Brien D; Bonafede M; Mansi JA; Boikos C
    Pediatr Infect Dis J; 2022 Sep; 41(9):769-774. PubMed ID: 35797705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of trivalent influenza vaccines in patients with chronic kidney disease undergoing hemodialysis: MF59-adjuvanted versus non-adjuvanted vaccines.
    Noh JY; Song JY; Choi WS; Lee J; Seo YB; Kwon YJ; Ko GJ; Cha DR; Kang YS; Lee YK; Cheong HJ; Kim WJ
    Hum Vaccin Immunother; 2016 Nov; 12(11):2902-2908. PubMed ID: 27802078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cumulative clinical experience with MF59-adjuvanted trivalent seasonal influenza vaccine in young children and adults 65 years of age and older.
    Lindert K; Leav B; Heijnen E; Barrett J; Nicolay U
    Int J Infect Dis; 2019 Aug; 85S():S10-S17. PubMed ID: 30904674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.